Regeneron Pharmaceuticals Inc (NASDAQ:REGN) plunged 21% in friday's trading session after analyst's downgrade


Shares of Regeneron plunged 20% after analysts at RBC Capital cut their rating on the stock to sector perform from outperform. Read previous story .

If we see the company's performance and development pipeline, this dip might be utilized as a buying opportunity.
Tags:

About author

Make it happen !!

0 comments

Leave a Reply